Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Operating Activities:
Net income	$ 24,321	$ 11,203	$ 8,799
Adjustments to reconcile net income to cash provided by operating activities:
Depreciation and amortization	30,627	23,282	1,298
Deferred income tax expense (benefit)	789	(599)	1,563
Loss on revaluation of derivatives	167	6,118
Debt extinguishment expenses		960
Stock compensation	1,252	2,073	1,275
Loss on sale of property, plant & equipment	555	35
Provision for doubtful accounts	533	1,241	253
Defined benefit plan expense	50	266	251
Excess tax benefit from equity awards	(171)	(3,257)
(Gain) Loss from equity investment	82	243	22
Changes in operating assets and liabilities:
Accounts receivable	(18,367)	(12,639)	(4,615)
Inventory	(5,847)	(4,624)	(4,285)
Prepaid expenses and other assets	(3,228)	1,937	(255)
Accounts payable	1,788	4,722	5,053
Accrued liabilities	4,314	3,266	2,094
Net cash provided by operating activities	36,865	34,227	11,453
Investing Activities:
Purchases of derivative financial instruments	(7,787)
Purchases of short-term investments			(11,612)
Sales and maturities of short-term investments		9,761	8,555
Purchase of non-controlling interest			(3,380)
Investment in subsidiary, net of cash acquired		(113,432)	(1,500)
Equity investment		(491)	97
Loan to equity investment	(590)	(860)
Cash invested in corporate owned life insurance	(265)	(266)	(266)
Purchase of property and equipment	(26,793)	(10,636)	(957)
Patent Costs		(37)	(17)
Proceeds from the sale of property and equipment	40
Net cash used in investing activities	(35,395)	(115,961)	(9,080)
Financing Activities:
Distribution paid to non-controlling interest	(290)
Cash paid for financing costs	(264)	(4,493)
Borrowing of Debt	3,326	138,168
Repayments of Debt	(22,953)	(110,775)
Proceeds from public offering of common stock	75,532
Proceeds from the sale of Series C Convertible Preferred Stock		61,403
Proceeds from the sale of embedded derivatives		2,610
Excess tax benefit from equity awards	171	3,257
Redemption of Series C Preferred Stock	(25,740)	(7,780)
Series C Preferred Stock Holders dividend		(1,362)
Proceeds from the exercise of Common Stock options	774	3,345
Proceeds from sale of common stock, net of cash expenses			2,438
Net cash used in financing activities	32,477	85,548	2,438
Foreign currency effect on cash and cash equivalents	366	(6,559)	96
Net (decrease) increase in cash and cash equivalents	34,313	(2,745)	4,907
Cash and cash equivalents at beginning of period	23,839	26,584	21,677
Cash and cash equivalents at end of period	58,152	23,839	26,584
Supplemental disclosure of cash flow information:
Cash paid for interest	3,545	3,963	52
Cash paid for taxes	8,445	5,322	182
Supplemental disclosure of non-cash transactions:
Issuance of Common Stock for Series C Preferred Stock redemption	7,780	7,780
Issuance of Common Stock for Series C Preferred Stock dividend	1,031	2,242
Common stock issued to directors and employees	429	669	17
W.E.T.
Financing Activities:
Proceeds from sale of W.E.T. equity to non-controlling interest	$ 1,921	$ 1,175